Abstract:BackgroundLung metastasis remains the primary cause of tumor-related mortality, with limited treatment options and unsatisfactory efficacy. In preclinical studies, T helper 9 (TH9) cells have shown promise in treating solid tumors. However, it is unclear whether TH9 cells can tackle more challenging situations, such as established lung metastases. Moreover, comprehensive exploration into the nuanced biological attributes of TH9 cells is imperative to further unravel their therapeutic potential.MethodsWe adoptively transferred TH1, TH9, and TH17 cells into subcutaneous,in situ, and established lung metastases models of osteosarcoma and triple-negative breast cancer, respectively, comparing their therapeutic efficacy within each distinct model. We employed flow cytometry and anin vivoimaging system to evaluate the accumulation patterns of TH1, TH9, and TH17 cells in the lungs after transfusion. We conducted bulk RNA sequencing onin vitrodifferentiated TH9 cells to elucidate the chemokine receptor CXCR4, which governs their heightened pulmonary tropism relative to TH1 and TH17 cell counterparts. Using Cd4creCxcr4flox/floxmice, we investigate the effects of CXCR4 on the lung tropism of TH9 cells. We performed mass spectrometry to identify the E3 ligase responsible for CXCR4 ubiquitination and elucidated the mechanism governing CXCR4 expression within TH9 cellular milieu. Ultimately, we analyzed the tumor immune composition after TH9 cell transfusion and evaluated the therapeutic efficacy of adjunctive anti-programmed cell death protein-1 (PD-1) therapy in conjunction with TH9 cells.ResultsIn this study, we provide evidence that TH9 cells exhibit higher lung tropism than TH1 and TH17 cells, thereby exhibiting exceptional efficacy in combating established lung metastases. CXCR4-CXCL12 axis is responsible for lung tropism of TH9 cells as ablating CXCR4 in CD4+T cells reverses their lung accumulation. Mechanistically, tumor necrosis factor receptor-associated factor 6 (TRAF6)-driven hyperactivation of NF-κB signaling in TH9 cells inhibited ITCH-mediated ubiquitination of CXCR4, resulting in increased CXCR4 accumulation and enhanced lung tropism of TH9 cells. Besides, TH9 cells’ transfusion significantly improved the immunosuppressed microenvironment. TH9 cells and anti-PD-1 exhibit synergistic effects in tumor control.ConclusionsOur findings emphasized the innate lung tropism of TH9 cells driven by the activation of TRAF6, which supports the potential of TH9 cells as a promising therapy for established lung metastases.

Enhancement of T cell infiltration via tumor-targeted Th9 cell delivery improves the efficacy of antitumor immunotherapy of solid tumors

Genetically engineered T cells for cancer immunotherapy

Th9 Cell Differentiation and Its Dual Effects in Tumor Development

Natural Lung-Tropic TH9 Cells: a Sharp Weapon for Established Lung Metastases

Optimizing Adoptive Cell Therapy for Solid Tumors via Epigenetic Regulation of T‐cell Destiny

Focusing on CD8+ T-cell phenotypes: improving solid tumor therapy

Soluble Expression of Fc-Fused T Cell Receptors Allows Yielding Novel Bispecific T Cell Engagers

Superantigen-fused T Cell Engagers for Tumor Antigen-Mediated Robust T Cell Activation and Tumor Cell Killing

Potentiating adoptive cell therapy using synthetic IL-9 receptors

One signal activated TIL enable potent anti-tumor activity across diverse solid tumor types

Promoting The Recruitment, Engagement, And Reinvigoration of Effector T Cells via An Injectable Hydrogel with A Supramolecular Binding Capability for Cancer Immunotherapy

Progress in T cell receptor-gene engineered T cell immunotherapy for solid tumors

Enhancing Efficacy of TCR-engineered CD4 + T Cells Via Coexpression of CD8α

Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy

Th9 cells promote antitumor immune responses in vivo

CCR10-mediated Enhancement of T Cell Trafficking for Improved Tumor Immunotherapy

Polyvalent Spherical Aptamer Engineered Macrophages: X-ray-actuated Phenotypic Transformation for Tumor Immunotherapy

CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy

Coengineering specificity, safety, and function into T cells for cancer immunotherapy

Liposome-based in situ antigen-modification strategy for "universal" T-cell-receptor engineered T cell in cancer immunotherapy

Grooved Microneedle Patch Augments Adoptive T Cell Therapy Against Solid Tumors via Diverting Regulatory T Cells